USFDA completes inspection of Lupin's Nagpur plant

Pharma major Lupin has confirmed the completion of the inspection by US health regulator for its Nagpur facility without making any observations.

In a BSE filing, Lupin "announced the successful completion of an inspection carried out by the United States Food and Drug Administration (USFDA) at its Nagpur facility. The inspection concluded without any observations".

Lupin said its Nagpur facility manufactures oral solid products.

Shares of Lupin were trading 2.09 per cent higher at Rs 767.50 on BSE.